Stock listing
NASDAQ:TPST Tempest Therapeutics, Inc. Stock
Home listing (NASDAQ) of Tempest Therapeutics, Inc.
Follow Tempest Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TPST
$0.287 USD -0.022 (-7.2%)
Close on Nov 20, 2026
- Day range
- $0.280 – $0.297 USDNov 20, 2026
- Volume
- 145,309 sharesNov 20, 2026
- Market cap
- $5.74M USDAt the close on Nov 20, 2026 · price × 20.00M shares outstanding
- 52-week range
- $0.280 – $4.220 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.67M USDMedian day 177,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TPST · Home | $0.287 USD | -0.022 (-7.2%) | 145,309 | $0.297 | $0.297 | $0.280 | $0.309 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TPST · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.287 | -0.022 | -7.2% | $0.297 | $0.297 | $0.280 | 145,309 | |
| $0.309 | -0.018 | -5.5% | $0.326 | $0.350 | $0.301 | 194,943 | |
| $0.327 | -0.015 | -4.2% | $0.342 | $0.342 | $0.301 | 180,785 | |
| $0.342 | -0.040 | -10.5% | $0.381 | $0.389 | $0.342 | 99,827 | |
| $0.382 | -0.001 | -0.3% | $0.383 | $0.390 | $0.364 | 150,065 | |
| $0.383 | -0.014 | -3.5% | $0.379 | $0.400 | $0.370 | 125,013 | |
| $0.397 | +0.023 | +6.1% | $0.428 | $0.477 | $0.379 | 1,467,834 | |
| $0.374 | +0.013 | +3.5% | $0.397 | $0.400 | $0.337 | 295,015 | |
| $0.361 | -0.019 | -5.0% | $0.390 | $0.408 | $0.361 | 227,677 | |
| $0.381 | +0.005 | +1.4% | $0.410 | $0.410 | $0.380 | 77,342 | |
| $0.375 | -0.088 | -19.0% | $0.479 | $0.480 | $0.371 | 308,095 | |
| $0.463 | -0.005 | -1.1% | $0.462 | $0.500 | $0.455 | 97,574 | |
| $0.469 | -0.003 | -0.7% | $0.497 | $0.500 | $0.464 | 140,361 | |
| $0.472 | -0.024 | -4.7% | $0.500 | $0.505 | $0.470 | 160,429 | |
| $0.496 | -0.038 | -7.1% | $0.533 | $0.547 | $0.490 | 140,906 | |
| $0.533 | -0.007 | -1.2% | $0.549 | $0.560 | $0.530 | 53,572 | |
| $0.540 | +0.029 | +5.7% | $0.510 | $0.540 | $0.510 | 100,043 | |
| $0.511 | +0.001 | +0.1% | $0.520 | $0.531 | $0.511 | 71,636 | |
| $0.510 | -0.001 | -0.2% | $0.508 | $0.521 | $0.501 | 65,901 | |
| $0.511 | -0.011 | -2.1% | $0.534 | $0.542 | $0.504 | 52,200 | |
| $0.522 | -0.006 | -1.1% | $0.516 | $0.550 | $0.516 | 188,500 | |
| $0.528 | -0.048 | -8.3% | $0.570 | $0.623 | $0.520 | 368,300 | |
| $0.576 | -0.024 | -4.0% | $0.600 | $0.628 | $0.573 | 138,300 | |
| $0.600 | -0.024 | -3.8% | $0.640 | $0.640 | $0.600 | 127,400 | |
| $0.624 | -0.011 | -1.7% | $0.668 | $0.669 | $0.620 | 67,100 | |
| $0.635 | 0.000 | 0.0% | $0.633 | $0.653 | $0.620 | 120,800 | |
| $0.635 | -0.046 | -6.8% | $0.696 | $0.696 | $0.635 | 179,100 | |
| $0.681 | -0.062 | -8.3% | $0.747 | $0.747 | $0.680 | 228,700 | |
| $0.743 | -0.017 | -2.2% | $0.763 | $0.778 | $0.740 | 163,600 | |
| $0.760 | -0.010 | -1.3% | $0.776 | $0.810 | $0.760 | 180,100 | |
| $0.770 | -0.021 | -2.7% | $0.786 | $0.795 | $0.765 | 147,100 | |
| $0.791 | +0.003 | +0.4% | $0.790 | $0.820 | $0.750 | 307,400 | |
| $0.788 | -0.005 | -0.6% | $0.786 | $0.800 | $0.770 | 217,600 | |
| $0.793 | -0.018 | -2.2% | $0.800 | $0.825 | $0.782 | 155,200 | |
| $0.811 | +0.005 | +0.6% | $0.824 | $0.850 | $0.780 | 2,271,700 | |
| $0.806 | -0.028 | -3.4% | $0.810 | $0.830 | $0.800 | 153,400 | |
| $0.834 | +0.024 | +3.0% | $0.805 | $0.840 | $0.800 | 265,000 | |
| $0.810 | -0.022 | -2.6% | $0.826 | $0.851 | $0.804 | 152,300 | |
| $0.832 | +0.003 | +0.4% | $0.825 | $0.849 | $0.800 | 256,400 | |
| $0.829 | -0.021 | -2.5% | $0.868 | $0.895 | $0.815 | 285,800 | |
| $0.850 | -0.072 | -7.8% | $0.901 | $0.919 | $0.850 | 442,400 | |
| $0.922 | -0.078 | -7.8% | $0.989 | $1.010 | $0.899 | 787,200 | |
| $1.000 | +0.226 | +29.2% | $0.780 | $1.090 | $0.770 | 3,611,100 | |
| $0.774 | -0.194 | -20.0% | $0.920 | $0.945 | $0.765 | 1,899,900 | |
| $0.968 | +0.073 | +8.2% | $0.840 | $1.090 | $0.840 | 4,799,000 | |
| $0.895 | -0.315 | -26.0% | $1.080 | $1.080 | $0.850 | 7,869,100 | |
| $1.210 | +0.455 | +60.3% | $1.070 | $1.480 | $0.967 | 104,597,900 | |
| $0.755 | -0.029 | -3.7% | $0.799 | $0.809 | $0.743 | 26,443,400 | |
| $0.784 | -0.028 | -3.4% | $0.800 | $0.822 | $0.752 | 138,700 | |
| $0.812 | +0.009 | +1.1% | $0.790 | $0.887 | $0.758 | 783,600 | |
| $0.803 | -0.106 | -11.7% | $0.950 | $0.950 | $0.800 | 391,000 | |
| $0.909 | -0.078 | -7.9% | $0.985 | $0.990 | $0.909 | 186,000 | |
| $0.987 | -0.043 | -4.2% | $1.020 | $1.030 | $0.976 | 199,600 | |
| $1.030 | -0.020 | -1.9% | $1.040 | $1.050 | $1.010 | 214,600 | |
| $1.050 | -0.050 | -4.5% | $1.100 | $1.100 | $1.040 | 181,900 | |
| $1.100 | +0.050 | +4.8% | $1.050 | $1.120 | $1.050 | 126,500 | |
| $1.050 | -0.040 | -3.7% | $1.070 | $1.080 | $1.031 | 177,300 | |
| $1.090 | +0.030 | +2.8% | $1.060 | $1.130 | $1.060 | 58,900 | |
| $1.060 | -0.020 | -1.9% | $1.092 | $1.100 | $1.040 | 62,300 | |
| $1.080 | 0.000 | 0.0% | $1.100 | $1.110 | $1.075 | 69,400 | |
| $1.080 | -0.030 | -2.7% | $1.109 | $1.110 | $1.070 | 51,700 | |
| $1.110 | +0.010 | +0.9% | $1.110 | $1.130 | $1.080 | 75,800 | |
| $1.100 | +0.060 | +5.8% | $1.050 | $1.140 | $1.010 | 198,800 | |
| $1.040 | +0.020 | +2.0% | $1.020 | $1.080 | $1.000 | 130,300 | |
| $1.020 | -0.050 | -4.7% | $1.050 | $1.075 | $1.005 | 89,500 |
Splits
3 splits since 2018 · NASDAQ:TPST · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-13 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:TPST
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Sep 15, 2026
Investor Presentation (September 2026)
Investor deck · 11 slides
Latest news
Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 13, 2026
Closed $0.342 (-10.5%) on Nov 16, 2026
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
Nov 11, 2026
Closed $0.397 (+6.1%) on Nov 11, 2026
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Oct 14, 2026
Closed $0.635 (-6.8%) on Oct 14, 2026
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Sep 23, 2026
Closed $0.922 (-7.8%) on Sep 23, 2026
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Sep 11, 2026
Closed $0.812 (+1.1%) on Sep 11, 2026
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $0.987 (-4.2%) on Sep 8, 2026
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $1.02 (-13.2%) on Aug 14, 2026
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Jul 21, 2026
Closed $0.99 (+4.0%) on Jul 21, 2026
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Jul 15, 2026
Closed $1.07 (+9.1%) on Jul 15, 2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Jun 4, 2026
Closed $1.27 (-2.3%) on Jun 5, 2026
Tempest Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 90 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 13 decks · latest Sep 15, 2026
Where Tempest Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TPST · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TPST | BOATS | United States | USD |
| gettex:3OS0 | gettex | Germany | EUR |
| Frankfurt:3OS0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41556 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41556 | LS Exchange | Germany | EUR |
| Munich:3OS0 | Munich | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.84M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.09
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tempest Therapeutics, Inc. · NASDAQ:TPST | US$5.74M | US$4.84M | n/a | n/a | n/a | n/a | n/a | n/a | 1.09 |
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Marvel Biosciences Corp · TSXV:MRVL | US$5.91M | US$6.04M | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 |
| Exicure, Inc. · NASDAQ:XCUR | US$5.89M | US$4.67M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.49 |
| Oncotelic Therapeutics Inc · OTC:OTLC | US$5.58M | US$5.52M | 0.0× | n/a | n/a | 0.0× | n/a | 0.0× | 0.07 |
| Theriva Biologics, Inc. · AMEX:TOVX | US$5.51M | US$461,120 | n/a | n/a | n/a | 0.5× | n/a | 0.3× | 2.65 |
| Hemostemix Inc · TSXV:HEM | US$5.35M | US$7.70M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Median of the others | US$5.93M | US$4.90M | 0.0× | 191× | 1.3× | 0.0× | 0.63 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.85 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Andrew Fang | Head of Business Development |
Board
| Director | Role |
|---|---|
| John W. Frederick | Board Member |
| Nancy Freda-Smith | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −10.5% |
| Q2 2026 | Aug 13, 2026 · After close | −13.3% |
| Q1 2026 | May 15, 2026 | −12.9% |
| Q4 2025 | Mar 30, 2026 · Before open | −12.1% |
| Q3 2025 | Nov 5, 2025 · Before open | +9.1% |
| Q2 2025 | Aug 11, 2025 · After close | +10.0% |
| Q1 2025 | May 13, 2025 · After close | −3.5% |
| Q4 2024 | Mar 17, 2025 · Before open | +1.8% |
| Q3 2024 | Nov 12, 2024 · After close | −10.5% |
| Q2 2024 | Aug 8, 2024 · After close | −14.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −6.3% |
| Q4 2023 | Mar 19, 2024 · After close | +0.5% |
| Q3 2023 | Nov 8, 2023 · After close | +16.3% |
| Q2 2023 | Aug 10, 2023 · After close | +1.6% |
| Q1 2023 | May 10, 2023 · After close | +2.9% |
| Q4 2022 | Mar 22, 2023 · After close | +6.5% |
| Q3 2022 | Nov 8, 2022 · Before open | −12.1% |
| Q2 2022 | Aug 15, 2022 · Before open | +15.8% |
| Q1 2022 | May 13, 2022 · Before open | +5.9% |
| Q4 2021 | Mar 29, 2022 · After close | −7.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 11 slides | Sep 15, 2026 |
| Investor Presentation (May 2026) | Investor deck | 23 slides | May 6, 2026 |
| Investor Presentation (February 2026) | Investor deck | 40 slides | Feb 11, 2026 |
| Technical Presentation (June 2022) | Technical | 17 slides | June 2022 |
| Millendo Therapeutics — Merger or Acquisition (March 2021) | Merger or acquisition | 23 slides | Mar 29, 2021 |
| Millendo Therapeutics — Investor Presentation (June 2020) | Investor deck | 15 slides | Jun 23, 2020 |
| Millendo Therapeutics — Corporate Update (April 2020) | Corporate update | 8 slides | Apr 6, 2020 |
| Millendo Therapeutics — Investor Presentation (January 2020) | Investor deck | 24 slides | Jan 13, 2020 |
| Millendo Therapeutics — Investor Presentation (March 2019) | Investor deck | 25 slides | Mar 22, 2019 |
| Millendo Therapeutics — Investor Presentation (January 2019) | Investor deck | 25 slides | Jan 7, 2019 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2019) | Technical | 24 slides | 2019 |
| OvaScience — Merger or Acquisition (August 2018) | Merger or acquisition | 20 slides | Aug 9, 2018 |
| OvaScience — Investor Presentation (January 2018) | Investor deck | 30 slides | Jan 8, 2018 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants Announced: about US$2.5M · US$0.805 a share · Warrants at US$0.805 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Sep 11, 2026 |
| Strategic investment of investment commitment Update: strategic investment Buyers: Factor Bioscience Inc. (investment commitment / financing support) Use of proceeds: Together with existing cash, expected to provide a runway to mid-2027 and potentially through key data milestones | Feb 4, 2026 |
| Registered direct offering of shares of common stock (or common stock equivalents) with concurrent private placement of short-term unregistered warran Closed: US$4.25M raised · US$3.625 a share · Warrants at US$3.5 for 18 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Primarily working capital and general corporate purposes | Nov 26, 2025 |
| Registered direct offering of shares of common stock (or common stock equivalents) Announced: about US$4.6M · US$6.25 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: single institutional investor (739,000 shares of common stock (or common stock equivalents)) Use of proceeds: Supporting the previously announced strategic alternative process, working capital and general corporate purposes | Jun 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 295.0K | 653.0K | ||
| Cost of revenue | 389.0K | 381.0K | 1.81M | 1.27M | 815.0K | 1.05M | 32.0K | 790.0K | 5.40M | |
| Gross profit | -389.0K | -381.0K | -1.81M | -1.27M | -815.0K | -1.05M | -32.0K | 267.0K | -4.75M | |
| Research and development | 12.6M | 28.5M | 17.5M | 22.5M | 17.2M | 14.4M | 27.8M | 14.4M | 18.3M | 21.6M |
| Selling, general and administrative | 14.0M | 13.6M | 11.7M | 12.1M | 9.82M | 4.91M | 17.6M | 8.69M | 27.7M | 49.2M |
| Operating income | -26.6M | -42.0M | -29.2M | -34.6M | -27.0M | -19.3M | -45.4M | -26.9M | -84.3M | -81.0M |
| Depreciation and amortization | 266.0K | 389.0K | 381.0K | 638.0K | 374.0K | 339.0K | 97.0K | 32.0K | 1.65M | 2.24M |
| EBITDA | -26.3M | -41.6M | -28.8M | -34.0M | -26.6M | -19.0M | -45.3M | -26.8M | -82.7M | -78.8M |
| Interest expense | 207.0K | 1.32M | 1.45M | 1.62M | 1.28M | 0 | 1.04M | 134.0K | 288.0K | 659.0K |
| Income before tax | -26.3M | -41.8M | -29.5M | -35.7M | -28.3M | -19.2M | -44.6M | -27.2M | -50.9M | -82.1M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 1.00K | -169.0K | 67.0K | 201.0K |
| Net income | -26.3M | -41.8M | -29.5M | -35.7M | -28.3M | -19.2M | -44.6M | -27.2M | -84.6M | -82.3M |
| Earnings per share, basic | -6.33 | -19.50 | -1.91 | -3.09 | -7.47 | -41.03 | -3.25 | -17.58 | -321.81 | -2.56 |
| Earnings per share, diluted | -6.33 | -19.50 | -1.91 | -3.09 | -7.47 | -41.03 | -3.25 | -17.58 | -321.81 | -2.56 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.71M | 30.3M | 39.2M | 31.2M | 51.8M | 18.8M | 62.5M | 73.3M | 17.6M | 43.9M |
| Short-term investments | 0 | 51.5M | 70.5M | |||||||
| Receivables | 450.0K | 15.0M | 260.0K | 1.28M | 2.33M | 1.03M | ||||
| Inventory | 1.58M | 686.0K | 1 | |||||||
| Current assets | 8.27M | 31.5M | 40.4M | 33.0M | 69.0M | 19.8M | 71.1M | 83.4M | 19.7M | 116.4M |
| Property, plant and equipment | 605.0K | 886.0K | 840.0K | 1.06M | 1.11M | 1.11M | 3.75M | 3.11M | 5.57M | |
| Total assets | 16.9M | 41.5M | 51.6M | 46.1M | 73.2M | 22.9M | 75.0M | 84.1M | 19.8M | 122.5M |
| Accounts payable | 1.04M | 2.45M | 845.0K | 1.11M | 991.0K | 1.07M | 1.50M | 2.00M | 1.30M | 2.18M |
| Current liabilities | 3.31M | 14.2M | 9.41M | 7.28M | 20.0M | 3.22M | 12.5M | 9.82M | 4.09M | 13.2M |
| Long-term debt | 0 | 6.26M | 10.4M | 15.1M | 0 | 168.0K | 383.0K | 599.0K | ||
| Total debt | 0 | 6.40M | 10.5M | 10.4M | 15.1M | 239.0K | 376.0K | 572.0K | 599.0K | |
| Total liabilities | 10.3M | 22.4M | 24.8M | 28.0M | 37.1M | 4.95M | 15.1M | 11.0M | 4.83M | 14.3M |
| Shareholders' equity | 6.67M | 19.1M | 26.8M | 18.1M | 36.1M | -68.8M | -50.4M | 71.0M | -130.7M | 108.2M |
| Shares outstanding | 4.93M | 3.38M | 22.0M | 10.5M | 6.91M | 527.3K | 18.3M | 13.4M | 246.3K | 35.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -26.8M | -33.0M | -27.4M | -31.1M | -26.0M | -19.0M | -41.2M | -23.6M | -20.3M | -61.7M |
| Capital spending | 0 | -435.0K | -170.0K | -562.0K | -135.0K | -50.0K | -397.0K | -36.0K | -4.00K | -2.59M |
| Free cash flow | -26.8M | -33.5M | -27.5M | -31.6M | -26.1M | -19.1M | -41.6M | -23.7M | -20.3M | -64.3M |
| Cash from investing | 0 | -435.0K | -170.0K | -562.0K | -97.0K | -6.00K | 3.99M | 1.93M | 458.0K | 8.29M |
| Cash from financing | 4.26M | 24.5M | 35.6M | 11.4M | 59.1M | 34.6M | 26.9M | 77.7M | -4.46M | 54.1M |
| Change in cash | -22.6M | -8.96M | 8.07M | -20.2M | 33.0M | -24.9M | -10.3M | 56.1M | -24.3M | 706.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 8-K · Current report | Nov 10, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 2, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Nov 2, 2026 | Annual report | SEC |
| 8-K · Current report | Oct 30, 2026 | Management or board change | SEC |
| DEF 14A · Proxy statement | Oct 26, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 20, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Oct 19, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Oct 16, 2026 | Meeting notice | SEC |
| D | Oct 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Oct 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 2, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 28, 2026 | Material contract | SEC |
| S-3 · Registration statement | Sep 25, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 17, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Sep 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Sep 15, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Sep 1, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 27, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 24, 2026 | Management or board change | SEC |
| S-1 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Aug 18, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 18, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 8-K · Current report | Aug 13, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Jul 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 28, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jul 22, 2026 | Material contract | SEC |
| DEF 14A · Proxy statement | Jul 17, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Jul 8, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 8, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Jul 7, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Jul 2, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 2, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 26, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| D | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jun 8, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 4, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 1, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | May 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 8-K · Current report | May 22, 2026 | Current report | SEC |
| 8-K · Current report | May 22, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | May 6, 2026 | Current report | SEC |
| 424B3 · Prospectus | Apr 10, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 10, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 10, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| D | Apr 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Apr 1, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2026 | Other filings | SEC |
| S-8 POS | Mar 31, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 30, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 25, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 23, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 25, 2026 | Current report | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 2, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Dec 31, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Dec 31, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Dec 30, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 12, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 9, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Dec 2, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 26, 2025 | Financing | SEC |
| 424B5 · Prospectus | Nov 25, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Nov 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 19, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 8-K · Current report | Jun 12, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 12, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 8-K · Current report | Apr 18, 2025 | Current report | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 6, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 24, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jan 24, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 31, 2024 | Current report | SEC |
| 8-K · Current report | Dec 6, 2024 | Material contract | SEC |
| DEF 14A · Proxy statement | Nov 12, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Oct 29, 2024 | Meeting notice | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Oct 10, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 10, 2024 | Material contract | SEC |
| 144 · Notice of proposed sale | Aug 13, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 9, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| UPLOAD · Letter from the SEC | Jul 23, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 19, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 20, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 20, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | May 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| S-8 POS | Nov 17, 2023 | Offer document | SEC |
| S-8 POS | Nov 17, 2023 | Offer document | SEC |
| S-8 POS | Nov 17, 2023 | Offer document | SEC |
| S-8 POS | Nov 17, 2023 | Offer document | SEC |
| S-8 POS | Nov 17, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 17, 2023 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 9, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 144 · Notice of proposed sale | Nov 2, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 30, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 12, 2023 | Offer document | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Tempest Therapeutics, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 19,995,358
- Fully diluted
- 19,995,358
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 19,995,358 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.50 · expire about May 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 19,995,358 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Carol Giltner Gallagher Other companies: PMV Pharmaceuticals, Inc. (Director · Since at least Nov 3, 2022); Atara Biotherapeutics, Inc. (Director · Since at least Jun 27, 2019); Certara, Inc. (Director · Jun 15, 2021 – Jun 15, 2021 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Metacrine Inc (Director · Sep 15, 2020 – Sep 15, 2020 · Past); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Turning Point Therapeutics Inc (Director · Jul 24, 2019 – Aug 17, 2022 · Past) | Director · Jun 20, 2019 – Jun 22, 2020 · Past |
| Richard Aldrich Other companies: KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 3, 2018 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Mar 6, 2023 · Past); PTC Therapeutics, Inc. (Director · Mar 7, 2013 – Jun 8, 2015 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Jun 10, 2014 · Past) | Director · Jun 11, 2012 – Dec 7, 2018 · Past |
| David Harding Other companies: T2 Biosystems, Inc. (Chief Commercial Officer · Oct 30, 2015 – Feb 9, 2017 · Past); Hologic Inc (Group VP & GM, Women's Health · Jun 28, 2013 – Nov 18, 2013 · Past) | Chief Commercial Officer · Apr 10, 2014 – Dec 9, 2014 · Past |
| Michael Raab Other companies: Ardelyx, Inc. (President & CEO, Director · Since at least Jan 19, 2017); Amicus Therapeutics Inc (Director · Since at least Jun 9, 2016) | Director · Since at least Jun 25, 2021 |
| Thomas Malley Other companies: Kiniksa Pharmaceuticals International, plc (Director · Since at least May 23, 2018); Kura Oncology, Inc. (Director · Since at least Oct 13, 2015) | Director · Jun 30, 2015 – Jun 13, 2017 · Past |
| Christophe Couturier Other companies: Avantor, Inc. (EVP, AMEA · Since at least May 16, 2019) | Chief Financial Officer · Sep 6, 2016 – Mar 2, 2017 · Past |
| John Yee Other companies: Apnimed, Inc. (Senior Vice President, Medical Affairs · Since at least Nov 5, 2026) | Director · Since at least Jun 4, 2026 |
| Julia C Owens Other companies: Metacrine Inc (Director · Apr 1, 2021 – May 18, 2022 · Past) | Executive Chair, Director · Dec 7, 2018 – Mar 17, 2021 · Past |
| Louis J Arcudi III Other companies: Aceragen Inc. (Chief Financial Officer · Jan 3, 2017 – Aug 13, 2018 · Past) | President and CEO, Director · Dec 7, 2018 – Feb 26, 2021 · Past |
| Matthew Angel Other companies: Ernexa Therapeutics Inc. (President and CEO, Director · May 26, 2022 – Jan 12, 2023 · Past) | CEO and President, Director · Since at least Feb 3, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Randall W Whitcomb Other companies: Insmed Incorporated (Director · Jan 10, 2014 – Mar 10, 2015 · Past) | Director · Dec 7, 2018 – Jun 20, 2019 · Past |
| Thomas W Dubensky Other companies: Aduro Biotech Inc (Chief Scientific Officer · Apr 14, 2015 – Aug 10, 2017 · Past) | President, Director · Jun 25, 2021 – Jan 3, 2023 · Past |
| Andrew Fang | Head of Business Development · Since at least May 14, 2026 |
| Geoffrey Nichol | Director · Since at least Jun 13, 2024 |
| John W. Frederick | Board Member · Since at least Oct 14, 2026 |
| Justin Trojanowski | Corporate Controller · Since at least Sep 30, 2022 |
| Nancy Freda-Smith | Board Member · Since at least Sep 23, 2026 |
| Ronit Simantov | Director · Since at least Jan 27, 2026 |
| Sam Whiting | Chief Medical Officer · Aug 13, 2025 – Nov 4, 2026 · Past |
| William Drake Richey | Director · Since at least Jun 4, 2026 |
Log in to ask 6ix AI your own questions about Tempest Therapeutics, Inc.